Nicolas Carboni

International Society of Differentiation, Inc. engages in development, research and communication in the fields of cell and developmental biology, molecular biology and oncology. The company was founded by Jean Louis Auguste Brachet in 1971 and is headquartered in St. Paul, MN.

Syndivia SAS engages in the development of treatment for cancer. Its product pipeline include SDV1001, for pancreatic cancer, colorectal cancer and TNBC; and SDV1101, for breast cancer and liposarcoma. The company is headquartered in Illkirch, France.

Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China.

Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners.

Alsace BioValley Association operates as a health innovation center. The private company is based in Illkirch, France.

Trophos SA engages in manufacturing and development of pharmaceutical products. It offers medicines to patients with conditions such as amyotrophic lateral sclerosis, spinal muscular atrophy and cardiac ischemia reperfusion injury. The company was founded by Antoine Beret and Michel Delaage in 1991 and is headquartered in Marseille, France.

Capital Grand Est SAS (Capital Grand Est) formerly known as Alsace Capital, is a private equity firm headquartered in France. Founded in 2012, the firm is wholly owned by Region Grand Est of France and has offices in Schiltigheim, France.

Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France.

Emosis SAS engages in research and experimental development on natural science and engineering. It addresses the unmet testing needs of patients presenting a broad range of conditions, such as cardiovascular and cerebrovascular diseases, cancer, pregnancy or surgical complications and complication of oral contraceptives, associated with bleeding and blood clotting disorders hemostasis and thrombosis in medical parlance. The company was founded by Aaron Tomer and Frederic Allemand in 2015 and is headquartered in Illikirch-Graffenstaden, France.

Bionext SA develops software applications for pharmaceuticals and biotechnology companies. The firm integrates big data and cloud computing, and OMICS data through computer simulations for enabling to visualize, understand, and correct actions of drugs in human cells, as well as in drug discovery processes. The company was founded by Laurent-Philippe Albou and Serge Henri Albou in 2009 and is headquartered in Strasbourg, France.

Inoviem Scientific SAS offers preclinical and clinical services that use cutting-edge proprietary technologies to speed up drug-development. Its services include preclinical and drug discovery, patient stratification and biomarkers clinical development. The company was founded by Pierre Eftekhari in 2011 and is headquartered in Strasbourg, France.